Century Therapeutics, Inc.
US ˙ NasdaqCM ˙ US15673T1007

Introduction

This page provides a comprehensive analysis of the known insider trading history of Joseph Jimenez. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Joseph Jimenez has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:PG / The Procter & Gamble Company Director 33,658
US:GM / General Motors Company Director 55,679
US:GRPH / Graphite Bio, Inc. Director 0
US:IPSC / Century Therapeutics, Inc. Director 19,872
US:CL / Colgate-Palmolive Company Director 22,950
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Joseph Jimenez. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases IPSC / Century Therapeutics, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in IPSC / Century Therapeutics, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

IPSC / Century Therapeutics, Inc. Insider Trades
Insider Sales IPSC / Century Therapeutics, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in IPSC / Century Therapeutics, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

IPSC / Century Therapeutics, Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Joseph Jimenez as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2025-06-11 2025-06-10 4 PG PROCTER & GAMBLE Co
Common Stock
A - Award 292 33,658 0.88
2025-03-12 2025-03-11 4 PG PROCTER & GAMBLE Co
Common Stock
A - Award 246 33,230 0.75
2024-12-11 2024-12-10 4 PG PROCTER & GAMBLE Co
Common Stock
A - Award 276 32,859 0.85
2024-10-09 2024-10-08 4 PG PROCTER & GAMBLE Co
Common Stock
A - Award 1,309 32,464 4.20
2024-09-11 2024-09-10 4 PG PROCTER & GAMBLE Co
Common Stock
A - Award 268 31,155 0.87
2024-06-12 2024-06-11 4 PG PROCTER & GAMBLE Co
Common Stock
A - Award 284 30,777 0.93
2024-03-13 2024-03-12 4 PG PROCTER & GAMBLE Co
Common Stock
A - Award 263 30,384 0.87
2023-12-13 2023-12-12 4 PG PROCTER & GAMBLE Co
Common Stock
A - Award 326 30,016 1.10
2023-10-11 2023-10-10 4 PG PROCTER & GAMBLE Co
Common Stock
A - Award 1,520 29,584 5.42
2023-09-13 2023-09-12 4 PG PROCTER & GAMBLE Co
Common Stock
A - Award 296 28,064 1.07
2023-06-14 2023-06-13 4 PG PROCTER & GAMBLE Co
Common Stock
A - Award 311 27,675 1.14
2023-03-15 2023-03-14 4 PG PROCTER & GAMBLE Co
Common Stock
A - Award 287 27,275 1.06
2022-12-14 2022-12-13 4 PG PROCTER & GAMBLE Co
Common Stock
A - Award 292 26,893 1.10
2022-10-12 2022-10-11 4 PG PROCTER & GAMBLE Co
Common Stock
A - Award 1,610 26,510 6.47
2022-09-15 2022-09-13 4 PG PROCTER & GAMBLE Co
Common Stock
A - Award 290 24,900 1.18
2022-06-16 2022-06-14 4 PG PROCTER & GAMBLE Co
Common Stock
A - Award 299 24,536 1.23
2022-03-09 2022-03-08 4 PG PROCTER & GAMBLE Co
Common Stock
A - Award 239 24,167 1.00
2022-01-04 2021-12-31 4 GM General Motors Co
Deferred Share Units
A - Award 5,816 55,679 11.66 55.88 324,998 3,111,343
2021-12-16 2021-12-14 4 PG PROCTER & GAMBLE Co
Common Stock
A - Award 253 23,866 1.07
2021-10-14 2021-10-12 4 PG PROCTER & GAMBLE Co
Common Stock
A - Award 1,408 23,547 6.36
2021-09-15 2021-09-14 4 PG PROCTER & GAMBLE Co
Common Stock
A - Award 241 22,139 1.10
2021-07-01 2021-06-29 4 GRPH Graphite Bio, Inc.
Series B Preferred Stock
C - Conversion -19,763 0 -100.00
2021-07-01 2021-06-29 4 GRPH Graphite Bio, Inc.
Common Stock
C - Conversion 8,126 161,941 5.28
2021-07-01 2021-03-17 4 GRPH Graphite Bio, Inc.
Stock Option (right to buy)
A - Award 12,469 12,469
2021-07-01 2021-03-11 4 GRPH Graphite Bio, Inc.
Series B Preferred Stock
A - Award 19,763 19,763 5.06 100,001 100,001
2021-07-01 2021-01-14 4 GRPH Graphite Bio, Inc.
Stock Option (right to buy)
M - Exercise -49,876 0 -100.00
2021-07-01 2021-01-14 4 GRPH Graphite Bio, Inc.
Common Stock
M - Exercise 49,876 153,815 47.99 0.30 14,963 46,144
2021-07-01 2021-01-13 4 GRPH Graphite Bio, Inc.
Stock Option (right to buy)
A - Award 49,876 49,876
2021-06-24 3 GRPH Graphite Bio, Inc.
Common Stock
153,815
2021-06-21 2021-06-17 4 IPSC Century Therapeutics, Inc.
Option (right to buy)
A - Award 19,872 19,872
2021-06-17 3 IPSC Century Therapeutics, Inc.
Common Stock
494,346
2021-06-10 2021-06-08 4 PG PROCTER & GAMBLE Co
Common Stock
A - Award 260 21,841 1.20
2021-03-10 2021-03-09 4 PG PROCTER & GAMBLE Co
Common Stock
A - Award 238 21,524 1.12
2021-01-05 2020-12-31 4 GM General Motors Co
Deferred Share Units
A - Award 866 49,863 1.77 18.32 15,865 913,490
2021-01-05 2020-12-31 4 GM General Motors Co
Deferred Share Units
A - Award 9,678 48,997 24.61 30.48 294,985 1,493,429
2020-12-09 2020-12-08 4 PG PROCTER & GAMBLE Co
Common Stock
A - Award 254 21,232 1.21
2020-10-14 2020-10-13 4 PG PROCTER & GAMBLE Co
Common Stock
A - Award 1,387 20,931 7.10
2020-09-09 2020-09-08 4 PG PROCTER & GAMBLE Co
Common Stock
A - Award 258 19,544 1.34
2020-06-10 2020-06-09 4 PG PROCTER & GAMBLE Co
Common Stock
A - Award 296 19,246 1.56
2020-03-12 2020-03-10 4 PG PROCTER & GAMBLE Co
Common Stock
A - Award 249 18,906 1.33
2020-01-03 2019-12-31 4 GM General Motors Co
Deferred Share Units
A - Award 1,451 39,319 3.83
2020-01-03 2019-12-31 4 GM General Motors Co
Deferred Share Units
A - Award 7,987 37,868 26.73
2019-12-12 2019-12-10 4 PG PROCTER & GAMBLE Co
Common Stock
A - Award 388 18,620 2.13
2019-10-10 2019-10-08 4 PG PROCTER & GAMBLE Co
Common Stock
A - Award 1,654 18,197 10.00
2019-09-11 2019-09-10 4 PG PROCTER & GAMBLE Co
Common Stock
A - Award 261 16,543 1.60
2019-06-12 2019-06-11 4 PG PROCTER & GAMBLE Co
Common Stock
A - Award 252 16,257 1.57
2019-03-14 2019-03-12 4 PG PROCTER & GAMBLE Co
Common Stock
A - Award 225 15,981 1.43
2019-01-03 2018-12-31 4 GM General Motors Co
Deferred Share Units
A - Award 1,095 29,881 3.80
2019-01-03 2018-12-31 4 GM General Motors Co
Deferred Share Units
A - Award 7,538 28,786 35.48
2018-12-12 2018-12-11 4 PG PROCTER & GAMBLE Co
Common Stock
A - Award 293 15,732 1.90
2018-10-11 2018-10-09 4 PG PROCTER & GAMBLE Co
Common Stock
A - Award 2,129 15,416 16.02
2018-09-12 2018-09-11 4 PG PROCTER & GAMBLE Co
Common Stock
A - Award 336 13,287 2.59
2018-06-14 2018-06-12 4 PG PROCTER & GAMBLE Co
Common Stock
A - Award 357 12,947 2.84
2018-03-14 2018-03-13 4 PG PROCTER & GAMBLE Co
Common Stock
A - Award 121 12,589 0.97
2018-03-06 3 PG PROCTER & GAMBLE Co
Common Stock
24,936
2018-03-06 3 PG PROCTER & GAMBLE Co
Common Stock
24,936
2018-01-03 2017-12-31 4 GM General Motors Co
Deferred Share Units
A - Award 726 21,248 3.54
2018-01-03 2017-12-31 4 GM General Motors Co
Deferred Share Units
A - Award 7,578 20,522 58.54
2017-01-04 2016-12-31 4 GM General Motors Co
Deferred Share Units
A - Award 454 12,944 3.63
2017-01-04 2016-12-31 4 GM General Motors Co
Deferred Share Units
A - Award 7,980 12,490 176.94
2016-01-05 2015-12-31 4 GM General Motors Co
Deferred Share Units
A - Award 86 4,510 1.94
2016-01-05 2015-12-31 4 GM General Motors Co
Deferred Share Units
A - Award 4,424 4,424
2015-08-03 2015-07-31 4 GM General Motors Co
Common Stock
P - Purchase 32,000 32,000 31.84 1,018,880 1,018,880
2015-06-19 3 GM General Motors Co
Common Stock
660
2015-06-19 3 GM General Motors Co
Common Stock
660
2015-01-05 2015-01-02 4 CL COLGATE PALMOLIVE CO
Common Stock
A - Award 190 22,950 0.83 69.48 13,201 1,594,566
2014-10-03 2014-10-01 4 CL COLGATE PALMOLIVE CO
Common Stock
A - Award 215 22,655 0.96 64.90 13,954 1,470,310
2014-07-03 2014-07-01 4 CL COLGATE PALMOLIVE CO
Common Stock
A - Award 184 22,333 0.83 68.16 12,541 1,522,217
2014-05-14 2014-05-12 4 CL COLGATE PALMOLIVE CO
Stock Option (Right to Buy)
A - Award 5,357 5,357
2014-05-14 2014-05-12 4 CL COLGATE PALMOLIVE CO
Common Stock
A - Award 2,678 22,063 13.81
2014-04-03 2014-04-01 4 CL COLGATE PALMOLIVE CO
Common Stock
A - Award 196 19,369 1.02 63.53 12,452 1,230,513
2014-01-06 2014-01-02 4 CL COLGATE PALMOLIVE CO
Common Stock
A - Award 192 19,087 1.02 64.79 12,440 1,236,647
2013-10-03 2013-10-01 4 CL COLGATE PALMOLIVE CO
Common Stock
A - Award 526 18,813 2.88 59.37 31,229 1,116,928
2013-09-03 2013-07-01 4 CL COLGATE PALMOLIVE CO
Common Stock
A - Award 108 18,201 0.60 57.97 6,261 1,055,112
2013-05-15 2013-05-13 4 CL COLGATE PALMOLIVE CO
Stock Option (Right to Buy)
A - Award 2,890 2,890
2013-05-15 2013-05-13 4 CL COLGATE PALMOLIVE CO
Common Stock
A - Award 1,488 9,011 19.78
2013-04-03 2013-04-01 4 CL COLGATE PALMOLIVE CO
Common Stock
A - Award 54 7,517 0.72 114.83 6,201 863,203
2013-01-04 2013-01-02 4 CL COLGATE PALMOLIVE CO
Common Stock
A - Award 59 7,429 0.80 106.28 6,270 789,539
2012-10-11 2012-10-10 4 CL COLGATE PALMOLIVE CO
Common Stock
A - Award 59 7,338 0.81 105.80 6,242 776,360
2012-07-05 2012-07-02 4 CL COLGATE PALMOLIVE CO
Common Stock
A - Award 63 7,247 0.88 100.06 6,304 725,135
2012-05-16 2012-05-14 4 CL COLGATE PALMOLIVE CO
Stock Option (Right to Buy)
A - Award 3,500 3,500
2012-05-16 2012-05-14 4 CL COLGATE PALMOLIVE CO
Common Stock
A - Award 2,200 7,184 44.14
2012-04-04 2012-04-02 4 CL COLGATE PALMOLIVE CO
Common Stock
A - Award 63 4,961 1.29 95.09 5,991 471,741
2012-01-05 2012-01-03 4 CL COLGATE PALMOLIVE CO
Common Stock
A - Award 68 4,876 1.41 91.18 6,200 444,594
2011-07-06 2011-07-01 4 CL COLGATE PALMOLIVE CO
Common Stock
A - Award 73 4,697 1.58 86.07 6,283 404,271
2011-04-05 2011-04-01 4 CL COLGATE PALMOLIVE CO
Common Stock
A - Award 82 2,025 4.22 78.60 6,445 159,157
2010-03-11 3 CL COLGATE PALMOLIVE CO
No Securities Owned
0
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)